Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sanai Health Industry Group Company Limited

三 愛 健 康 產 業 集 團 有 限 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

APPOINTMENT OF INTERNAL CONTROL ADVISER

Reference is made to the regulatory news release published by The Stock Exchange of Hong Kong Limited (the ''Stock Exchange'') on 3 September 2020 (the ''News Release'') in relation to, amongst other things, the censure of Sanai Health Industry Group Company Limited (the ''Company'') for its breaches of Rules 13.49(1) of the Rules Governing the Listing of Securities on The Stock Exchange (the ''Listing Rules'') and a number of its former and current directors for breaching the Listing Rules and/or the Director's undertaking.

APPOINTMENT OF INTERNAL CONTROL ADVISER

Pursuant to the sanctions 3 and 4 of the Listing Committee of the Stock Exchange, the Company has appointed Zhonghui Anda Risk Services Limited as the independent professional adviser of the Company (the ''Internal Control Adviser'') to conduct a thorough review of and make recommendations to improve the Company's internal controls to ensure compliance with the Listing Rules. Such appointment has been approved by the Stock Exchange.

The review report of the Internal Control Adviser containing such recommendations is expected to be completed within two months from the publication of the News Release. The Company will furnish the Listing Division with the Internal Control Adviser's written report on the Company's full implementation of the Internal Control Adviser's recommendations within four months from the publication of the News Release.

By order of the Board

Sanai Health Industry Group Company Limited

Chen Chengqing

Chairman

Hong Kong, 17 September 2020

- 1 -

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing (Chairman), Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and two independent non-executive directors, namely, Mr. Wang Zihao and Mr. Long Jun.

- 2 -

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Wuyi International Pharmaceutical Co. Ltd. published this content on 17 September 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2020 14:34:03 UTC